These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 28005281)

  • 1. Harnessing self-assembly to enable modular vaccine design.
    Biotechnol Bioeng; 2017 Feb; 114(2):244. PubMed ID: 28005281
    [No Abstract]   [Full Text] [Related]  

  • 2. A self-adjuvanting supramolecular vaccine carrying a folded protein antigen.
    Hudalla GA; Modica JA; Tian YF; Rudra JS; Chong AS; Sun T; Mrksich M; Collier JH
    Adv Healthc Mater; 2013 Aug; 2(8):1114-9. PubMed ID: 23436779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic peptide vaccines: success at last.
    Meloen RH; Casal JI; Dalsgaard K; Langeveld JP
    Vaccine; 1995 Jul; 13(10):885-6. PubMed ID: 7483758
    [No Abstract]   [Full Text] [Related]  

  • 4. Structural Properties of Potential Synthetic Vaccine Adjuvants - TLR Agonists.
    Honegr J; Soukup O; Doležal R; Malinak D; Penhaker M; Prymula R; Kuca K
    Curr Med Chem; 2015; 22(29):3306-25. PubMed ID: 26295466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvants enhancing an integral immune response to antigens. 15-17 September, 2004, Modern Vaccine/Adjuvant Formulation: impact on future development (MVAF 2004), Prague.
    van der Laan JW
    Expert Rev Vaccines; 2005 Feb; 4(1):15-8. PubMed ID: 15757468
    [No Abstract]   [Full Text] [Related]  

  • 6. Lipid-core-peptide system for self-adjuvanting synthetic vaccine delivery.
    Skwarczynski M; Toth I
    Methods Mol Biol; 2011; 751():297-308. PubMed ID: 21674338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics.
    Gupta S; Termini JM; Kanagavelu S; Stone GW
    Immunol Res; 2013 Dec; 57(1-3):303-10. PubMed ID: 24198065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Self-Assembly as a Molecular Strategy to Improve Immunotherapy.
    Froimchuk E; Carey ST; Edwards C; Jewell CM
    Acc Chem Res; 2020 Nov; 53(11):2534-2545. PubMed ID: 33074649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines.
    Alving CR; Rao M; Steers NJ; Matyas GR; Mayorov AV
    Expert Rev Vaccines; 2012 Jun; 11(6):733-44. PubMed ID: 22873129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of potent immunological adjuvants for vaccine construction.
    McElrath MJ
    Semin Cancer Biol; 1995 Dec; 6(6):375-85. PubMed ID: 8938276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleic acids presenting polymer nanomaterials as vaccine adjuvants.
    Comberlato A; Paloja K; Bastings MMC
    J Mater Chem B; 2019 Nov; 7(41):6321-6346. PubMed ID: 31460563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting nanoparticles to dendritic cells for immunotherapy.
    Cruz LJ; Tacken PJ; Rueda F; Domingo JC; Albericio F; Figdor CG
    Methods Enzymol; 2012; 509():143-63. PubMed ID: 22568905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-Molecule Carbohydrate-Based Immunostimulants.
    Marzabadi CH; Franck RW
    Chemistry; 2017 Feb; 23(8):1728-1742. PubMed ID: 27385422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technological advances in antigen delivery and synthetic peptide vaccine developmental strategies.
    Olive C; Toth I; Jackson D
    Mini Rev Med Chem; 2001 Nov; 1(4):429-38. PubMed ID: 12369968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant.
    Azmi F; Ahmad Fuaad AA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Bioorg Med Chem; 2014 Nov; 22(22):6401-8. PubMed ID: 25438764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of Nucleic Acid-Based Adjuvant for Cancer Immunotherapy].
    Kobiyama K; Ishii KJ
    Gan To Kagaku Ryoho; 2015 Sep; 42(9):1040-5. PubMed ID: 26469159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine.
    Ahmed KK; Geary SM; Salem AK
    J Pharm Sci; 2016 Mar; 105(3):1173-9. PubMed ID: 26886334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for designing an immunocontraceptive vaccine based on zona pellucida synthetic peptides and recombinant antigen.
    Kaul R; Afzalpurkar A; Gupta SK
    J Reprod Fertil Suppl; 1996; 50():127-34. PubMed ID: 8984175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles.
    O'Hagan DT; Ott GS; Van Nest G
    Mol Med Today; 1997 Feb; 3(2):69-75. PubMed ID: 9060004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New and safe "oral" live vaccines based on lactobacillus.
    Claassen E; Van Winsen R; Posno M; Boersma WJ
    Adv Exp Med Biol; 1995; 371B():1553-8. PubMed ID: 7502855
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.